Comparative Pharmacology
Head-to-head clinical analysis: DOXY 100 versus MECLAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 100 versus MECLAN.
DOXY 100 vs MECLAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic